Jubilant Pharmova recommends ₹5 dividend, sets Aug 26 AGM date
NiveshIQ
NSE: JUBLPHARMA · Healthcare
Jubilant Pharmova Ltd.
₹977.40▲ ₹13.95 (+1.45%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on JUBLPHARMA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Jubilant Pharmova Ltd.
Jubilant Pharmova Limited is an integrated pharmaceutical company operating in India, the Americas, Europe, and internationally. The company's core business spans six segments, including radiopharmaceuticals, allergy immunotherapy, contract development and manufacturing, generics, contract research and development, and proprietary novel drugs. The Radiopharma segment offers products used in disease diagnosis and treatment, while the Allergy Immunotherapy segment provides diagnostic devices and immunotherapy products. Jubilant Pharmova has reported 14% revenue growth in FY 2026, driven by strong growth in CDMO and Radiopharma. The company expects margin recovery in FY 2027 as new lines stabilize and investments pay off. With a revenue of ₹7918 Cr and net income of ₹433 Cr, Jubilant Pharmova
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹6,703 Cr +6.70% | ₹7,234 Cr +7.90% | ₹8,279 Cr +14.40% |
| EBITDA Margin | 13.44% | 16.22% | 0.00% |
| Net Profit | ₹73.00 Cr | ₹836.00 Cr +1045.20% | ₹397.00 Cr -52.50% |
| EPS | ₹4.84 | ₹52.69 | ₹25.02 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Jubilant Pharmova seeks re-appointment of two MDs
Jubilant Pharmova: కీలక పదవుల్లో కొనసాగింపు.. వాటాదారుల అనుమతి కోరిన కంపెనీ!
🔒
+ 3 more stories about Jubilant Pharmova Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹2, 290 Cr, PAT ₹119 Cr, EPS ₹7.50. Growth context: revenue QoQ +7.9%, PAT QoQ +112.5%. Street verdict: strong miss, revenue surprise -27.1%, PAT surprise -23.2%.
Management commentary points to new capacity addition and capex deployment as the primary near-term growth lever, with e...
FY26 (last completed FY): revenue ₹8, 279 Cr, PAT ₹397 Cr, EPS ₹25.02. Year-on-year: revenue YoY +14.4%, PAT YoY -52.5%....
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for JUBLPHARMA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track JUBLPHARMA alongside your other holdings
Unlock full JUBLPHARMA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Jubilant Pharmova Ltd.?
NiveshIQ detects active intelligence signals for Jubilant Pharmova Ltd. (JUBLPHARMA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Jubilant Pharmova Ltd.?
Jubilant Pharmova Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,593,929.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.